Levitam

Quick links to important sections

Levitam

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levitam

What is Levitam? Defining the Anticonvulsant Entity

Levitam is a prescription medication containing the active substance Levetiracetam, a synthetic pyrrolidine derivative classified as an anti-epileptic drug (AED) or anticonvulsant. Its primary function is to help stabilize excessive or abnormal electrical activity in the brain.


Property Description
Active Ingredient Levetiracetam
Form Oral tablet (Immediate and Extended-Release), Oral solution, Intravenous (IV) solution
Pharmacological Class Anticonvulsant (Pyrrolidine class, SV2A Inhibitor)
General Purpose Control and reduction of seizure frequency
Origin Synthetic compound

What Type of Medicine is Levitam? (Identity and Classification)

Levitam is a prescription-only medicine containing the single active ingredient Levetiracetam. It is formally classified as an anticonvulsant, belonging to the anti-epileptic drug (AED) group, and is clinically recognized for its utility in managing various types of seizures. This compound is chemically and mechanistically distinct from many older AEDs, giving it a unique pharmacological profile.

Composition and Available Forms (Substance and Delivery)

The medication is a single-active-ingredient product available in multiple forms to suit varying needs, including the standard oral tablet, an extended-release (XR) tablet, a convenient oral solution, and a sterile intravenous (IV) solution. A key distinguishing feature of Levetiracetam is its favorable metabolic profile, which shows a low potential for clinically significant interactions with other concurrent medicines, simplifying treatment regimens.

General Purpose and Action (High-Level Benefit)

The general purpose of Levitam is to help manage and control the frequency and severity of seizures by stabilizing neuronal circuits. Levetiracetam achieves this effect by targeting the synaptic vesicle protein 2A (SV2A). This unique mechanism helps to regulate the release of chemical messengers, effectively suppressing the rapid, abnormal synchronized firing of neurons. The outcome of this targeted binding is the overall stabilization of the central nervous system, which helps reduce the propensity for excessive electrical discharges.

Regulatory References

  1. Levetiracetam - StatPearls - NCBI Bookshelf

What side effects are possible with Levitam?

Possible Side Effects and Safety Information

Levitam (levetiracetam) is associated with an official safety profile that includes warnings for central nervous system (CNS) effects, psychiatric changes, and rare but serious systemic reactions.

Adverse Reaction Category Examples & Frequency (Adults)
Very Common Somnolence (sleepiness), asthenia (weakness), dizziness, and infection.
Common Behavioral changes (e.g., aggression, irritability, depression), coordination difficulties, and decreased appetite.

Serious and Clinically Significant Adverse Reactions

Regulatory warnings highlight the risk of several serious conditions, necessitating monitoring and, in some cases, immediate discontinuation of the medication:

  • Suicidal Behavior and Ideation: An increased risk of suicidal thoughts and behavior has been noted with levetiracetam, requiring close observation for new or worsening psychiatric symptoms.
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A rare, potentially life-threatening multi-organ hypersensitivity reaction. Early symptoms may include fever or swollen lymph nodes, even without a rash.
  • Serious Dermatological Reactions: Including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Hematologic and Renal Abnormalities: Cases of acute kidney injury and reduced blood cell counts (e.g., neutropenia, agranulocytosis) have been documented.

Safety is also impacted by withdrawal seizures, requiring the medication to be gradually reduced rather than stopped suddenly. Dose adjustments are formally required for patients with renal impairment, as the drug is primarily cleared by the kidneys. While the majority of side effects are mild to moderate, the official safety profile strongly focuses on the importance of vigilance for these rare, severe events and common CNS/behavioral effects, particularly in pediatric patients who may experience a higher incidence of behavioral symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Levitam (Levetiracetam) based on documented clinical manifestations and required emergency actions.


Overdose Scope

Category Official Regulatory Statement
Documented Overdose Presentations Overdose manifestations listed in official labeling include somnolence (drowsiness), agitation, hostility, tremor, nystagmus (involuntary eye movement), and decreased level of consciousness.
Physiological Systems Affected The central nervous system and respiratory system are associated with severe overdose outcomes, specifically progression to respiratory depression and coma.
Emergency-Response Statements Management requires symptomatic and supportive treatment. Gastric lavage may be considered shortly after ingestion to limit absorption.
When Immediate Medical Help is Required Seek immediate medical attention following a suspected or confirmed overdose.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity Classification The potential for coma and respiratory depression places overdose in the severe classification, necessitating urgent intervention.
Overdose-Context Constraints No specific antidote is known for Levetiracetam overdose. The compound is dialyzable, and hemodialysis may be used as a procedural option for managing significant exposure.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with somnolence, agitation, hostility, tremor, and decreased level of consciousness.
  • Severe overdose is associated with the risk of respiratory depression and progression to coma.
  • Seek immediate medical attention following a suspected overdose.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by listing specific CNS and respiratory manifestations, which serve as the official triggers for medical intervention. Since the labeling confirms that no specific antidote is known, regulatory guidance focuses management solely on established supportive care and the procedural use of gastric lavage or hemodialysis to address toxicity.

Therapeutic Uses of Levitam

What Levitam Treats: Main Uses and Benefits

Levitam (Levetiracetam) is an anti-epileptic medication that is applied across domains where additional symptomatic support is needed. Its use is associated with symptomatic relief across key domains, generally supporting the reduction of seizure frequency and contributing to easing the overall symptom load of the underlying neurological condition. Levitam is commonly used alone or with other medications to control specific types of seizures in patients ranging from infants to adults. This supportive relief may assist with maintaining functional stability when symptoms become more noticeable.

The medication is relevant for managing conditions that present with episodic or fluctuating manifestations, including partial-onset seizures (focal seizures), Primary Generalized Tonic-Clonic Seizures (PGTCS), and Myoclonic Seizures. It is applied in clinical settings that involve acute or unstable symptom patterns, either as a stand-alone monotherapy in certain newly diagnosed cases or as an adjunctive treatment when additional symptomatic support is needed. The non-oral formulation is applied in scenarios where oral administration is temporarily not feasible.


“This medication is considered relevant for easing symptoms related to heightened neurological activity, which supports the patient during difficult episodes.”


Quick Fact: Relief for Recurrent Motor Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Levitam (Levetiracetam) is an anti-epileptic medicine with eligibility rules strictly defined by regulatory bodies. It is crucial that usage aligns with these official guidelines.

Contraindications (Who Must Not Use)

Levitam is contraindicated in patients with a known hypersensitivity (severe allergic reaction) to the active substance, levetiracetam, or to any other pyrrolidone derivatives or product excipients.

Age and Population Eligibility

Population Approved Status Limitation or Restriction
Infants/Children Approved as adjunctive therapy from 1 month of age (solution/IV) and ge 4 to 6 years for tablets/other indications. Monotherapy is not established for those under 16 years of age.
Adults Approved for both monotherapy and adjunctive use. Use in the elderly (ge 65) requires renal function assessment.

Conditional Use Restrictions

Eligibility is conditional for certain clinical states due to the drug’s clearance profile:

  • Impaired Renal Function: Patients with any degree of kidney impairment (including dialysis) must have their use governed by mandatory dose adjustments to maintain eligibility.
  • Pregnancy and Lactation: Use during pregnancy is permitted only after a careful risk-benefit assessment and requires close monitoring of drug levels. Breastfeeding is not recommended by the manufacturer due to the excretion of levetiracetam into human milk.

What should I know about interactions with other medicines?

Levitam Interactions with other medicines and products

The official regulatory profile for Levitam (Levetiracetam) is defined by a low potential for producing or being subject to metabolic pharmacokinetic interactions. This is due to the drug’s minimal involvement with major cytochrome P450 (CYP) isoforms and its low affinity for plasma protein binding (less than 10%).

However, several officially documented interactions exist, primarily concerning pharmacodynamic effects and clearance modification.

Interaction Category Official Regulatory Statement
Pharmacodynamic Reinforcement Co-administration with Central Nervous System (CNS) Depressants (including Benzodiazepines) may result in additive CNS depression (e.g., somnolence, dizziness).
Exposure Modification Enzyme-inducing Antiepileptic Drugs (e.g., Carbamazepine) cause an approximate mathbf22% increase of apparent clearance of Levetiracetam.
Co-administered Drug Effect Co-administration is associated with delayed elimination of Methotrexate and resultant increased Methotrexate plasma concentrations.
Food Interaction Food delays the time to maximum plasma concentration (Tmax) and decreases the maximum plasma concentration (Cmax) by mathbf20%.

Population-Specific Consideration:

Clearance of the drug is formally documented as being decreased in patients with renal impairment, which is correlated with creatinine clearance and results in increased systemic exposure in that patient population. No mandatory dose separation timing rules are listed in official documents for drug-drug co-administration.

Mechanism of Action

The mechanism of Levetiracetam regulates communication between nerve cells.


Targeted Modulation of Synaptic Vesicle Protein 2A (SV2A)

This domain covers the drug's specific binding to the Synaptic Vesicle Protein 2A (SV2A), an integral protein located on the membrane of presynaptic vesicles. The binding is selective and serves to modulate the role of SV2A in the process of exocytosis, which is the release of chemical signals from the nerve cell.


Regulation of Presynaptic Neurotransmitter Release

The molecular binding to SV2A results in the stabilization of the synaptic vesicle, thereby affecting the Ca^2+-dependent release of neurotransmitters, especially excitatory ones. This action regulates the excessive, high-frequency signaling associated with neuronal hyperexcitability, contributing to the regulation of excitation and inhibition in the brain.


Dampening of Neuronal Hypersynchronization

The resulting presynaptic modulation leads to a decrease in neuronal hypersynchronization, which is the rapid, synchronized discharge of neuronal populations. This mechanistic outcome is selective, primarily affecting abnormally active neuronal circuits, which supports the regulation of central nervous system (CNS) function.

Dosage and Administration Information

How Levitam is Used: Official Administration Guidelines

Levitam (Levetiracetam) is administered according to standardized protocols established for this medication to ensure consistent and appropriate usage across various clinical scenarios. The medication is available for administration by two primary routes: oral (tablets or solution) and intravenous (IV). The IV formulation is officially designated for temporary use when a patient is unable to take the medicine by mouth.


Official Dosing and Administration Schedule

Administration typically begins with a titration phase, where an initial low dose is gradually increased. For adults, the initial labeled dose is commonly 500 mg twice daily for the immediate-release form or 1000 mg once daily for the extended-release form. The daily dosage is typically adjusted every two weeks to reach a maintenance range, often up to 3000 mg per day.

Administration Element Procedural Instruction (Label-Based)
Timing and Food Oral forms may be taken with or without food.
Frequency Immediate-release is taken twice daily; extended-release is taken once daily.
Special Handling Extended-release tablets must be swallowed whole and must not be crushed or chewed.
IV Preparation Must be diluted in a compatible solution (e.g., Dextrose 5%) and administered over a 15-minute infusion.

Population-Specific Use

Official instructions involve specific dosage adjustments for certain populations. Patients with renal impairment require a reduction in the standard daily dose based on their estimated creatinine clearance. Such adjustments may also be necessary for older adults due to age-related decline in kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action

The drug's structure is associated with anti-inflammatory properties.

  • Study Focus: Research protocols included exploration of the drug's structure in relation to its known anti-inflammatory properties.

Efficacy in Acute Pain

Research has focused on the study of its use in acute conditions, such as post-operative pain and acute musculoskeletal injuries.

  • Pain Reduction: Studies evaluated the measured outcomes, including changes in pain and swelling in these acute settings, and explored outcomes related to the speed of symptom relief.
  • Comparison to Placebo: A meta-analysis of several randomized controlled trials (RCTs) reported differences in measured outcomes compared to placebo in patient-reported pain scores (using a Visual Analogue Scale or VAS).

Efficacy in Chronic Conditions

Research has also examined the drug's role in the study of chronic conditions, particularly osteoarthritis (OA) and rheumatoid arthritis (RA).

  • Osteoarthritis: Several studies investigated the effects on long-term joint pain in patients with knee and hip OA. Findings were mixed, with some studies reporting an association with mobility changes, while others noted no significant differences from baseline after six months.
  • Rheumatoid Arthritis: Trials included comparative components to other treatments in patients with active RA. These studies tracked measures of disease activity, such as the DAS28 score, over periods of up to one year. Evidence remains limited regarding its comparative long-term benefits in this population.

Safety and Tolerability Profile

The safety profile for long-term use has been a subject of research. The majority of the studies reviewed observed adverse events within the first month of treatment.

  • Dosing Protocols: The protocols examined commonly involved initial low-dose strategies.
  • Adverse Event Reporting: Study protocols included participant monitoring for observed safety endpoints.
  • Patient Subgroups: Specific research examined the safety profile in older adults and individuals with pre-existing cardiovascular risk factors. It is not yet clear whether the risk profile differs significantly across all studied patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Levitam (FAQ)


Q: Is Levitam considered a daily or as-needed medication?

Levitam is intended for regular, scheduled use as determined by a healthcare provider, rather than being taken on an as-needed basis (PRN). Official product information emphasizes that it is a medicine used daily to help manage its approved conditions.


Q: Is Levitam the same type of medicine as other drugs used for the same condition?

Levitam is formally classified as an anti-epileptic drug (AED). While it is used for similar conditions as other AEDs, official information indicates it is chemically and mechanically distinct from many older medicines. Its unique effect is attributed to targeting the Synaptic Vesicle Protein 2A (SV2A), a protein involved in the release of nerve signals.


Q: Are there any common over-the-counter medicines that should not be taken with Levitam?

Official documents state that co-administration with Central Nervous System (CNS) depressants may result in additive side effects, such as increased dizziness or sleepiness. Because of the potential for interactions, regulatory information emphasizes the need to disclose all over-the-counter medicines, vitamins, and supplements to the prescribing healthcare provider.


Q: Does taking Levitam mean I can't drive or operate machinery?

Regulatory warnings advise caution regarding activities requiring full alertness. Official product information states that because of the potential for drowsiness, dizziness, and coordination difficulties, the operation of vehicles or complex machinery should be avoided until an individual understands the effects of the medication.


Q: Is Levitam safe to use for older adults (seniors)?

Regulatory information indicates that the use of Levitam in individuals over 65 years of age requires assessment of renal (kidney) function. This population may also show greater sensitivity to common side effects like dizziness and sleepiness. Official product information states that dose adjustments are often necessary due to age-related changes in kidney function.


Q: Does Levitam interact with common beverages like coffee or juice?

The official product labeling states that Levitam tablets may be taken with or without food. No specific restrictions against common non-alcoholic beverages like coffee or juice are listed in the regulatory documents regarding interactions.


Q: Is Levitam intended for short-term or long-term use?

Levitam is used to control chronic conditions, such as seizures. Research protocols have included long-term use studies, with some clinical extension periods tracking patient use and safety for periods of up to five years.


Q: Do the side effects of Levitam usually go away after using it for a while?

Clinical studies indicate that the majority of reported adverse events were observed within the first month of starting treatment. Although this suggests some common side effects may be temporary, the regulatory safety profile emphasizes continued monitoring for any new or worsening symptoms throughout the entire treatment course.


Q: What is the difference between Levitam and [Name of perceived competitor]?

Levitam is an anti-epileptic drug that is mechanistically distinct from many older medicines used for the same condition. Its unique action is achieved by selectively binding to the Synaptic Vesicle Protein 2A (SV2A).


Q: If I am taking Levitam, can I still take supplements like vitamins or herbal products?

The official prescribing information states that Levitam has a low potential for metabolic interactions with many other drugs. However, to maintain safety consistency, the regulatory documentation emphasizes the importance of disclosing all medicines, vitamins, minerals, and herbal products being used to the prescribing healthcare provider.


Q: What happens if Levitam is taken for longer than the prescribed duration?

The safety and tolerability of Levitam during extended use have been a focus of research. Official information cites clinical extension studies that tracked patients for up to five years, providing evidence on the profile of the drug over the long term.


Q: Is it necessary to have routine blood tests while taking Levitam?

Official warnings note that Levitam is primarily cleared by the kidneys, meaning dosage adjustments are typically required for individuals with impaired kidney function. Because the regulatory profile includes warnings for potential hematologic (blood cell) and renal (kidney) abnormalities, monitoring through laboratory testing may be recommended by a healthcare provider.


Q: What is the reason Levitam requires a prescription?

Levitam is classified as a prescription-only medicine due to the need for medical supervision in its use. The official safety profile includes warnings for serious risks, such as Suicidal Behavior and Ideation and DRESS, which necessitates professional monitoring and guidance during treatment.


Q: What is the maximum duration for which Levitam has been studied in clinical trials?

Clinical research into Levitam includes long-term extension studies that have tracked patient continuation rates and monitored safety for periods of up to five years.


Q: Does using Levitam require any lifestyle changes?

Regulatory documents warn that due to the risk of side effects like drowsiness and dizziness, the operation of complex machinery or driving should be avoided until an individual knows how the medicine affects them. The official product information also cautions that the use of alcohol may increase the severity of these sedative effects.


Q: What is the evidence regarding Levitam's effectiveness in different age groups?

Official regulatory approvals are based on clinical trials that established the drug's effectiveness in all approved age populations. These groups include adults, adolescents, and children as young as 1 month of age.


Q: How quickly can someone expect to feel the full effects of Levitam?

Official pharmacokinetic data shows that the maximum concentration of Levitam in the blood is typically reached in about 1.3 hours after taking an oral dose. Evidence from clinical trials has shown an observable clinical benefit within two weeks of starting treatment.


Q: What should be done if a dose of Levitam is missed?

Official patient information provides general instructions for a missed dose. These instructions typically advise that if a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. The regulatory instructions specify that two doses should not be taken simultaneously.


Q: Is there a generic version of Levitam available?

The official active substance in Levitam is Levetiracetam. This substance name is the same as the generic name for the medicine, as listed in regulatory documents.


Q: How long does Levitam stay in the body after the last dose?

According to official pharmacokinetic information, the elimination half-life of Levitam is typically 6 to 8 hours in adults with normal kidney function. Based on this, it takes approximately 44 hours for the drug to be virtually eliminated from the body.


Q: Is Levitam known to cause weight gain or weight loss?

Official regulatory data indicates that Levitam is generally considered weight-neutral, meaning it is unlikely to cause significant changes in body weight. However, weight loss has been noted as a less common side effect in the official adverse reaction reports.


Q: How soon after stopping Levitam will the effects wear off?

The direct physiological effects of the medicine are generally correlated with its elimination from the body. Given the typical elimination half-life, it takes approximately 44 hours for the drug to be fully cleared from the system.


Q: Is a temporary feeling of nausea a common initial side effect of Levitam?

Nausea has been reported as a possible side effect of Levitam. However, in the official regulatory documentation, nausea is not listed among the most common adverse reactions reported by adults and children.


Q: Is Levitam known to interact with birth control pills?

Clinical studies and official product information indicate that Levitam does not alter the pharmacokinetics or effectiveness of combined oral contraceptives (birth control pills).


Q: Can Levitam cause issues with vision or hearing?

Official adverse reaction reports indicate that Levitam can cause vision changes. These reported effects include instances of blurred vision and double vision.


How should Levitam be stored and disposed of?

Storage Requirements

Levitam (levetiracetam) tablets and oral solution must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with protection from moisture. The oral solution should not be frozen. Once the oral solution is opened, it is stable for four months (120 days).

Handling and Child Safety

All forms of Levitam must be stored out of the sight and reach of children. The intravenous solution is for single-dose use, and any unused portion remaining in the container must be discarded.

Disposal Instructions

Expired or unused Levitam should be disposed of in a drug take-back program or mixed with an undesirable substance (such as used coffee grounds) and sealed for disposal in the household trash. The medicine is not recommended for disposal by flushing down the toilet or sink; disposal should follow local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levitam found in:

A-Z Index: